Patent ID: 11896605
Assignee: GLYCOM A/S
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 10:
11. A method for reducing mast cell mediated visceral hypersensitivity and/or mast cell mediated visceral pain in a non-infant human, the method comprising:
selecting an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human;
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing the mast cell mediated visceral hypersensitivity and/or pain by administering to the non-infant human a daily dose of from about 3 g to about 10 g of the one or more neutral HMOs; and
selectively increasing expression of intestinal goblet cell genes to improve mucosal barrier function in gastrointestinal tract of the non-infant human by administering to the non-infant human the daily dose of the one or more neutral HMOs.